{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:29:38Z","timestamp":1785796178540,"version":"3.56.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.6055-25","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:07:31Z","timestamp":1761170851000},"page":"1553-1559","source":"Crossref","is-referenced-by-count":1,"title":["Early Recovery from Cryptogenic NORSE Following Repeated C-NORSE Score Assessment and Cyclophosphamide Treatment"],"prefix":"10.2169","volume":"65","author":[{"given":"Ryotaro","family":"Okochi","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Shimohama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kitasato University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap 34: 417-420, 2005.","DOI":"10.47102\/annals-acadmedsg.V34N7p417"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gaspard N, Foreman BP, Alvarez V, et al.; the Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 85: 1604-1613, 2015.","DOI":"10.1212\/WNL.0000000000001940"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59: 739-744, 2018.","DOI":"10.1111\/epi.14016"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia 59: 745-752, 2018.","DOI":"10.1111\/epi.14022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Iizuka T, Kanazawa N, Kaneko J, et al. Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy. Neurol Neuroimmunol Neuroinflamm 4: e396, 2017.","DOI":"10.1212\/NXI.0000000000000396"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hanin A, Cespedes J, Dorgham K, et al. Cytokines in new-onset refractory status epilepticus predict outcomes. Ann Neurol 94: 75-90, 2023.","DOI":"10.1002\/ana.26627"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hanin A, Zhang L, Huttner AJ, et al. Single-cell transcriptomic analyses of brain parenchyma in patients with new-onset refractory status epilepticus (NORSE). Neurol Neuroimmunol Neuroinflamm 11: e200259, 2024.","DOI":"10.1212\/NXI.0000000000200259"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Guillemaud M, Chavez M, Firas K, et al. Identification of distinct biological groups of patients with cryptogenic NORSE via inflammatory profiling. Neurol Neuroimmunol Neuroinflamm 12: e200403, 2025.","DOI":"10.1212\/NXI.0000000000200403"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Wickstrom R, Taraschenko O, Dilena R, et al.; the International NORSE Consensus Group. International consensus recommendations for management of New Onset Refractory Status Epilepticus (NORSE) including Febrile Infection-Related Epilepsy Syndrome (FIRES): Summary and Clinical Tools. Epilepsia 63: 2827-2839, 2022.","DOI":"10.1111\/epi.17391"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Donnelly JP, Kasatwar N, Hafeez S, et al. Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab. Epilepsy Behav Rep 4: 100431, 2021.","DOI":"10.1016\/j.ebr.2021.100431"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Watanabe T, Nakamori M, Ishikawa K, et al. Reversible brain atrophy in cryptogenic new-onset refractory status epilepticus. Intern Med 62: 1835-1842, 2023.","DOI":"10.2169\/internalmedicine.0465-22"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Yorichika Y, Neshige S, Sakahara H, et al. Early initiation of intravenous cyclophosphamide and one-year outcome in super-refractory cryptogenic-new onset refractory status epilepticus. Epilepsia Open 10: 307-313, 2025.","DOI":"10.1002\/epi4.13055"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lai YC, Muscal E, Wells E, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 7: 2467-2474, 2020.","DOI":"10.1002\/acn3.51229"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cabezudo-Garc\u00eda P, Mena-V\u00e1zquez N, Ciano-Petersen NL, Oliver-Martos B, Serrano-Castro PJ. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: a systematic review. Neurologia (Engl Ed) 39: 629-638, 2024.","DOI":"10.1016\/j.nrleng.2022.03.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yanagida A, Kanazawa N, Kaneko J, et al. Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Neurol Neuroimmunol Neuroinflamm 7: e849, 2020.","DOI":"10.1212\/NXI.0000000000000849"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jang Y, Ahn SH, Park K, et al. Prognosis prediction and immunotherapy optimization for cryptogenic new-onset refractory status epilepticus. J Neurol Neurosurg Psychiatry 96: 26-37, 2024.","DOI":"10.1136\/jnnp-2024-334285"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6055-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:30:01Z","timestamp":1780716601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6055-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6055-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"6055-25"}}